{"id":26262,"date":"2023-11-29T11:15:11","date_gmt":"2023-11-29T10:15:11","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=26262"},"modified":"2023-11-29T11:15:11","modified_gmt":"2023-11-29T10:15:11","slug":"impilo-investerar-i-stille","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/impilo-investerar-i-stille\/","title":{"rendered":"Impilo investerar i Stille"},"content":{"rendered":"<p class=\"preamble\">Impilo har \u00e5tagit sig att teckna aktier i en riktad emission som genomf\u00f6rs av Stille AB (publ). Impilos tecknings\u00e5tagande, som motsvarar ett investeringsbelopp om cirka 220 MSEK, \u00e4r bl.a. villkorat av att en extra bolagsst\u00e4mma i Stille godk\u00e4nner den riktade emissionen samt att Impilos investering godk\u00e4nns av Inspektionen f\u00f6r strategiska produkter enligt lagen (2023:560) om granskning av utl\u00e4ndska direktinvesteringar.<\/p>\n<p>Stille utvecklar, tillverkar och marknadsf\u00f6r medicintekniska produkter f\u00f6r specialistkirurger v\u00e4rlden \u00f6ver. Stille grundades 1841 och \u00e4r ett av v\u00e4rldens \u00e4ldsta f\u00f6retag inom medicinteknik. Stilles aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market.<\/p>\n<p>Impilo \u00e4r ett nordiskt investeringsbolag som fokuserar p\u00e5 l\u00e5ngsiktiga investeringar i h\u00e5llbara h\u00e4lso- och sjukv\u00e5rdsf\u00f6retag som \u00e4r verksamma inom l\u00e4kemedel, medicinsk teknik, h\u00e4lso- och sjukv\u00e5rdstj\u00e4nster och andra h\u00e4lsorelaterade omr\u00e5den.<\/p>\n<p>Impilo r\u00e5dges av Mannheimer Swartling i samband med investeringen i Stille.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Impilo har \u00e5tagit sig att teckna aktier i en riktad emission som genomf\u00f6rs av Stille AB (publ). Impilos tecknings\u00e5tagande, som motsvarar ett investeringsbelopp om cirka\u2026<\/p>\n","protected":false},"author":18,"featured_media":26263,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-26262","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-eu-och-konkurrensratt","business-group-private-equity","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":26262,"en":26266},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26262"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=26262"}],"version-history":[{"count":1,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26262\/revisions"}],"predecessor-version":[{"id":26265,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26262\/revisions\/26265"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/26263"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=26262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=26262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=26262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}